Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: Results Through 48 Weeks of a Phase 3, Multicenter, Randomized, Double-Blinded, Etanercept- and Placebo-Controlled Study (CIMPACT)

Certolizumab pegol is an Fc-free, PEGylated anti-tumor necrosis factor biologic.; In this phase 3 study, both certolizumab doses improved psoriasis symptoms at Week 12 that was maintained, following re-randomization, through Week 48 with a safety profile consistent with its class.; The higher dose of certolizumab may provide superior efficacy.

https://ift.tt/2GWT7ht